Proactive therapeutic drug monitoring of infliximab leads to durability of treatment in children with Inflammatory Bowel Disease

被引：0
|
作者：
Chuah, C. W. [1 ]
Eldredge, J. [1 ]
Magoffin, A. [1 ]
O'Loughlin, E., V [1 ]
Park, C. J. [2 ]
Puppi, J. [1 ]
Siew, S. [1 ,3 ]
Stormon, M. [1 ]
Thacker, K. [1 ]
Dutt, S. [1 ,3 ]
机构：
[1] Childrens Hosp Westmead, Dept Gastroenterol, Westmead, Australia
[2] Australian Natl Univ, Sydney Adventist Hosp, Clin Sch, Sch Med & Psychol, Canberra, Australia
[3] Univ Sydney, Childrens Hosp Westmead Clin Sch, Sydney Sch Med, Sydney, Australia
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.1321
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1147
引用
收藏
页码：i2099 / i2099
页数：1
相关论文
共 50 条
  • [31] Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review
    Ballesta-Lopez, Octavio
    Centelles-Oria, Maria
    Remedios Marques-Minana, Maria
    Eduardo Megias-Vericat, Juan
    Luis Poveda-Andres, Jose
    FARMACIA HOSPITALARIA, 2021, 45 : 56 - 63
  • [32] Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study
    Paul, Stephane
    Del Tedesco, Emilie
    Marotte, Hubert
    Rinaudo-Gaujous, Melanie
    Moreau, Amelie
    Phelip, Jean-Marc
    Genin, Christian
    Peyrin-Biroulet, Laurent
    Roblin, Xavier
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (12) : 2568 - 2576
  • [33] THE IMPACT OF THERAPEUTIC DRUG MONITORING DURING BIOSIMILAR INFLIXIMAB SWITCH IN INFLAMMATORY BOWEL DISEASE
    Ranjan, Ravi
    Myers, Sally
    Crissop, Linda
    Ritchie, Susan
    Maw, Frances
    Sebastian, Shaji
    Dhar, Anjan
    GUT, 2018, 67 : A74 - A74
  • [34] The impact of therapeutic drug monitoring during biosimilar infliximab switch in inflammatory bowel disease
    Ranjan, R.
    Myers, S.
    Crissop, L.
    Ritchie, S.
    Maw, F.
    Sebastian, S.
    Dhar, A.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S335 - S335
  • [35] Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease
    Kolho, Kaija-Leena
    FRONTIERS IN PEDIATRICS, 2021, 8
  • [36] Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study
    Paul, Stephane
    Del Tedesco, Emilie
    Marotte, Hubert
    Clavel, Lea
    Phelip, Jean Marc
    Peyrin-Biroulet, Laurent
    Roblin, Xavier
    GASTROENTEROLOGY, 2013, 144 (05) : S92 - S92
  • [37] Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (02) : 369 - 370
  • [38] The use of infliximab therapeutic drug monitoring in virtual biologics clinic for inflammatory bowel disease (IBD) leads to clinically durable results
    Sagar, R.
    Lenti, M.
    Clark, T.
    Rafferty, H.
    Gracie, D.
    Ford, A.
    O'Connor, A.
    Hamlin, J.
    Ahmad, T.
    Selinger, C.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S484 - S485
  • [39] Optimal Interval for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Stable Infliximab Maintenance Treatment
    Hong, S. N.
    Yujin, L.
    Boram, P.
    Soon, J. Ok
    Ho, K. Young
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I745 - I745
  • [40] Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial
    Bossuyt, Peter
    Pouillon, Lieven
    Claeys, Sophie
    D'Haens, Soetkin
    Hoefkens, Eveline
    Strubbe, Beatrijs
    Marichal, Denis
    Peeters, Harald
    JOURNAL OF CROHNS & COLITIS, 2022, 16 (02): : 199 - 206
12345